EGFR and non-small cell lung carcinoma: In conclusion, the findings of the ICTAN trial demonstrated that icotinib for 12 or 6 months prolonged DFS, OS, and BMFS compared with observation for patients with completely resected stage II-IIIA EGFR-mutated NSCLC after adjuvant chemotherapy.